Clearside Biomedical(CLSD) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Development Partners - - Use of Suprachoroidal Drug Delivery Featured in Over 15 Presentations at Major Ophthalmic Medical Meetin ...